Clinical Trial Update: Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin [EARLY_Phase 1]

View source ↗

Summary

Early-phase pilot trial evaluating MN-504 cobiotic formulation's effect on the efficacy and tolerability of Metformin in Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MN-504 cobiotic formulation (MN-504 cobiotic formulation)
• metformin (metformin)

Snippet

Sponsor: NuMe Health | Conditions: Type 2 Diabetes | EARLY_Phase 1 | Status: COMPLETED